Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Renal Cell | 77 | 2025 | 3186 | 5.040 |
Why?
|
Kidney Neoplasms | 75 | 2025 | 4282 | 4.300 |
Why?
|
Pyrroles | 32 | 2016 | 1121 | 3.030 |
Why?
|
Indoles | 32 | 2016 | 1834 | 2.650 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 26 | 2025 | 11872 | 1.410 |
Why?
|
Imidazoles | 11 | 2017 | 1168 | 1.010 |
Why?
|
Bone Neoplasms | 14 | 2024 | 2561 | 0.990 |
Why?
|
Angiogenesis Inhibitors | 11 | 2019 | 2057 | 0.990 |
Why?
|
Prostatic Neoplasms | 22 | 2024 | 11094 | 0.960 |
Why?
|
Indazoles | 9 | 2018 | 306 | 0.950 |
Why?
|
Urinary Bladder Neoplasms | 9 | 2024 | 2184 | 0.920 |
Why?
|
Diphosphonates | 5 | 2007 | 625 | 0.880 |
Why?
|
Phenylurea Compounds | 9 | 2021 | 533 | 0.810 |
Why?
|
Antineoplastic Agents | 32 | 2021 | 13643 | 0.790 |
Why?
|
Androgen Antagonists | 8 | 2024 | 1411 | 0.660 |
Why?
|
Anilides | 6 | 2025 | 413 | 0.580 |
Why?
|
Deoxycytidine | 3 | 2015 | 886 | 0.580 |
Why?
|
Cystectomy | 5 | 2024 | 603 | 0.570 |
Why?
|
Neoplasm Metastasis | 24 | 2022 | 4891 | 0.560 |
Why?
|
Orchiectomy | 4 | 2013 | 465 | 0.550 |
Why?
|
Carcinoma, Transitional Cell | 4 | 2023 | 790 | 0.530 |
Why?
|
Pyridines | 10 | 2025 | 2888 | 0.510 |
Why?
|
Protein Kinase Inhibitors | 16 | 2023 | 5690 | 0.500 |
Why?
|
Prednisone | 3 | 2014 | 1566 | 0.480 |
Why?
|
Interferon-alpha | 9 | 2014 | 910 | 0.460 |
Why?
|
Nephrectomy | 5 | 2024 | 928 | 0.450 |
Why?
|
Disease-Free Survival | 22 | 2024 | 6850 | 0.440 |
Why?
|
Technetium Tc 99m Medronate | 1 | 2012 | 134 | 0.400 |
Why?
|
Bone Density Conservation Agents | 4 | 2008 | 791 | 0.400 |
Why?
|
Sirolimus | 3 | 2016 | 1540 | 0.370 |
Why?
|
Receptors, Fibroblast Growth Factor | 1 | 2012 | 193 | 0.370 |
Why?
|
Dioxoles | 1 | 2011 | 96 | 0.370 |
Why?
|
Tetrahydroisoquinolines | 1 | 2011 | 81 | 0.370 |
Why?
|
Radiation Injuries | 2 | 2016 | 1194 | 0.370 |
Why?
|
Urogenital Neoplasms | 2 | 2003 | 130 | 0.360 |
Why?
|
Radium | 2 | 2024 | 70 | 0.360 |
Why?
|
Benzenesulfonates | 2 | 2011 | 170 | 0.350 |
Why?
|
Neoplasm Staging | 19 | 2024 | 11218 | 0.350 |
Why?
|
RANK Ligand | 1 | 2012 | 321 | 0.340 |
Why?
|
Gastrointestinal Diseases | 2 | 2016 | 1203 | 0.340 |
Why?
|
Cost-Benefit Analysis | 2 | 2020 | 5536 | 0.330 |
Why?
|
Camptothecin | 2 | 2023 | 599 | 0.330 |
Why?
|
Aged | 62 | 2025 | 171343 | 0.320 |
Why?
|
Male | 85 | 2025 | 364142 | 0.300 |
Why?
|
Middle Aged | 65 | 2025 | 223257 | 0.290 |
Why?
|
Molecular Targeted Therapy | 6 | 2019 | 2823 | 0.280 |
Why?
|
Humans | 123 | 2025 | 766766 | 0.280 |
Why?
|
Taxoids | 4 | 2014 | 665 | 0.280 |
Why?
|
Neovascularization, Pathologic | 3 | 2019 | 2631 | 0.280 |
Why?
|
Niacinamide | 4 | 2014 | 419 | 0.270 |
Why?
|
Sarcoma | 2 | 2022 | 1802 | 0.260 |
Why?
|
Computer Simulation | 1 | 2020 | 6259 | 0.260 |
Why?
|
Lymphocytes | 1 | 2014 | 2605 | 0.260 |
Why?
|
Clinical Trials, Phase III as Topic | 5 | 2019 | 878 | 0.250 |
Why?
|
Kaplan-Meier Estimate | 10 | 2018 | 6512 | 0.250 |
Why?
|
Osteoblastoma | 1 | 2005 | 24 | 0.250 |
Why?
|
Models, Economic | 2 | 2020 | 719 | 0.250 |
Why?
|
Immunotherapy | 3 | 2023 | 4747 | 0.250 |
Why?
|
Tourniquets | 1 | 2006 | 111 | 0.240 |
Why?
|
Gonadotropin-Releasing Hormone | 2 | 2010 | 1142 | 0.240 |
Why?
|
Maximum Tolerated Dose | 4 | 2013 | 895 | 0.240 |
Why?
|
Drug Administration Schedule | 8 | 2016 | 4853 | 0.240 |
Why?
|
Calcaneus | 1 | 2006 | 144 | 0.230 |
Why?
|
Neoplasm Invasiveness | 4 | 2024 | 3609 | 0.230 |
Why?
|
Antibodies, Monoclonal | 4 | 2023 | 9244 | 0.230 |
Why?
|
Pyrrolidines | 1 | 2006 | 339 | 0.230 |
Why?
|
Quinolines | 4 | 2021 | 769 | 0.220 |
Why?
|
Vascular Endothelial Growth Factor A | 5 | 2018 | 3511 | 0.220 |
Why?
|
Lung Diseases | 1 | 2014 | 1941 | 0.220 |
Why?
|
Drug Resistance, Neoplasm | 5 | 2013 | 5329 | 0.210 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2012 | 2426 | 0.210 |
Why?
|
Aged, 80 and over | 26 | 2024 | 59550 | 0.210 |
Why?
|
Paclitaxel | 2 | 2023 | 1727 | 0.210 |
Why?
|
Treatment Outcome | 27 | 2023 | 65273 | 0.200 |
Why?
|
Combined Modality Therapy | 10 | 2024 | 8540 | 0.200 |
Why?
|
Prostate-Specific Antigen | 6 | 2014 | 2463 | 0.200 |
Why?
|
Prognosis | 15 | 2024 | 29948 | 0.200 |
Why?
|
Treatment Failure | 4 | 2012 | 2659 | 0.200 |
Why?
|
Dose-Response Relationship, Drug | 8 | 2021 | 10745 | 0.200 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2008 | 1536 | 0.200 |
Why?
|
Testicular Neoplasms | 3 | 2015 | 805 | 0.190 |
Why?
|
Alkaline Phosphatase | 3 | 2014 | 855 | 0.190 |
Why?
|
Neutrophils | 1 | 2014 | 3782 | 0.180 |
Why?
|
Disease Progression | 10 | 2014 | 13640 | 0.180 |
Why?
|
Osteoclasts | 1 | 2004 | 713 | 0.170 |
Why?
|
Antineoplastic Protocols | 1 | 2020 | 48 | 0.170 |
Why?
|
Urethra | 2 | 2016 | 406 | 0.160 |
Why?
|
Female | 50 | 2025 | 396520 | 0.160 |
Why?
|
Fatigue | 3 | 2015 | 1555 | 0.150 |
Why?
|
Survival Analysis | 7 | 2021 | 10100 | 0.150 |
Why?
|
Drug Delivery Systems | 1 | 2009 | 2210 | 0.150 |
Why?
|
Proportional Hazards Models | 8 | 2018 | 12534 | 0.150 |
Why?
|
Medical Oncology | 3 | 2022 | 2340 | 0.150 |
Why?
|
Vascular Endothelial Growth Factor Receptor-3 | 3 | 2013 | 118 | 0.140 |
Why?
|
Osteoporosis | 1 | 2007 | 1581 | 0.140 |
Why?
|
Hematology | 1 | 2021 | 243 | 0.140 |
Why?
|
Adult | 32 | 2025 | 223307 | 0.140 |
Why?
|
Seminoma | 2 | 2015 | 135 | 0.130 |
Why?
|
Receptors, Nerve Growth Factor | 2 | 1996 | 199 | 0.130 |
Why?
|
Bone Remodeling | 3 | 2018 | 577 | 0.130 |
Why?
|
Gingival Neoplasms | 1 | 2016 | 21 | 0.130 |
Why?
|
Interleukin-7 | 1 | 1996 | 146 | 0.130 |
Why?
|
Macrophage Colony-Stimulating Factor | 1 | 1996 | 186 | 0.130 |
Why?
|
Immunoconjugates | 1 | 2023 | 976 | 0.130 |
Why?
|
Finger Phalanges | 1 | 2016 | 41 | 0.130 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2016 | 2060 | 0.120 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 5 | 2017 | 661 | 0.120 |
Why?
|
Tissue Distribution | 1 | 2019 | 2275 | 0.120 |
Why?
|
Radiography | 4 | 2014 | 6968 | 0.120 |
Why?
|
Drug Synergism | 1 | 2019 | 1756 | 0.120 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2021 | 1144 | 0.120 |
Why?
|
Gossypol | 1 | 2014 | 23 | 0.120 |
Why?
|
Radionuclide Imaging | 2 | 2012 | 1986 | 0.120 |
Why?
|
Steroid 17-alpha-Hydroxylase | 1 | 2014 | 100 | 0.110 |
Why?
|
Asthenia | 1 | 2013 | 16 | 0.110 |
Why?
|
Calcium Channel Blockers | 1 | 1997 | 687 | 0.110 |
Why?
|
Salvage Therapy | 3 | 2012 | 1274 | 0.110 |
Why?
|
Catheter Ablation | 2 | 2006 | 2786 | 0.110 |
Why?
|
Naphthalenes | 1 | 2014 | 198 | 0.110 |
Why?
|
Bone and Bones | 3 | 2012 | 2559 | 0.110 |
Why?
|
Neoplasms | 3 | 2021 | 22350 | 0.110 |
Why?
|
Clinical Protocols | 1 | 2019 | 1437 | 0.110 |
Why?
|
Survival Rate | 7 | 2019 | 12825 | 0.110 |
Why?
|
Clinical Trials as Topic | 7 | 2011 | 8045 | 0.100 |
Why?
|
Quality-Adjusted Life Years | 1 | 2020 | 1740 | 0.100 |
Why?
|
Scalp | 1 | 2016 | 390 | 0.100 |
Why?
|
L-Lactate Dehydrogenase | 1 | 2014 | 411 | 0.100 |
Why?
|
Muscle, Smooth | 1 | 2016 | 931 | 0.100 |
Why?
|
Glomerular Filtration Rate | 1 | 2021 | 2232 | 0.100 |
Why?
|
Phosphorylcholine | 1 | 2012 | 152 | 0.100 |
Why?
|
Lymphocyte Count | 1 | 2014 | 794 | 0.100 |
Why?
|
Receptor Cross-Talk | 1 | 2012 | 118 | 0.090 |
Why?
|
Retrospective Studies | 14 | 2023 | 81635 | 0.090 |
Why?
|
Lymphopenia | 1 | 2013 | 299 | 0.090 |
Why?
|
Perioperative Care | 1 | 2019 | 1043 | 0.090 |
Why?
|
Administration, Oral | 6 | 2015 | 4018 | 0.090 |
Why?
|
Neoplasms, Hormone-Dependent | 2 | 2003 | 409 | 0.090 |
Why?
|
Interleukin-8 | 1 | 2013 | 702 | 0.090 |
Why?
|
Neutropenia | 1 | 2015 | 894 | 0.090 |
Why?
|
Time Factors | 11 | 2017 | 40149 | 0.090 |
Why?
|
Neurons | 4 | 1996 | 9515 | 0.080 |
Why?
|
Drug Therapy, Combination | 1 | 2020 | 6307 | 0.080 |
Why?
|
Placebos | 1 | 2014 | 1659 | 0.080 |
Why?
|
Acute Kidney Injury | 1 | 2021 | 1946 | 0.080 |
Why?
|
Receptors, Platelet-Derived Growth Factor | 2 | 2007 | 178 | 0.080 |
Why?
|
Muscles | 2 | 2023 | 1576 | 0.080 |
Why?
|
Phthalazines | 2 | 2008 | 397 | 0.080 |
Why?
|
Watchful Waiting | 1 | 2012 | 492 | 0.070 |
Why?
|
Hemoglobins | 1 | 2014 | 1531 | 0.070 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2011 | 614 | 0.070 |
Why?
|
Quality of Life | 7 | 2014 | 13476 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2019 | 10384 | 0.070 |
Why?
|
Nomograms | 1 | 2008 | 235 | 0.070 |
Why?
|
Interdisciplinary Communication | 1 | 2012 | 932 | 0.070 |
Why?
|
Fractures, Bone | 2 | 2010 | 2043 | 0.070 |
Why?
|
Myocardial Ischemia | 1 | 1997 | 2132 | 0.070 |
Why?
|
Drug Discovery | 1 | 2014 | 1065 | 0.070 |
Why?
|
Referral and Consultation | 3 | 2014 | 3618 | 0.070 |
Why?
|
Patient Care Team | 2 | 2020 | 2519 | 0.070 |
Why?
|
Hypertension | 2 | 2015 | 8616 | 0.070 |
Why?
|
DNA Methylation | 1 | 2020 | 4427 | 0.060 |
Why?
|
Early Detection of Cancer | 1 | 2020 | 3236 | 0.060 |
Why?
|
Tumor Suppressor Proteins | 1 | 2016 | 2801 | 0.060 |
Why?
|
Vascular Endothelial Growth Factors | 1 | 2007 | 748 | 0.060 |
Why?
|
Urologic Diseases | 1 | 2008 | 246 | 0.060 |
Why?
|
Carcinoma | 1 | 2017 | 2324 | 0.060 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2008 | 364 | 0.060 |
Why?
|
Receptors, Death Domain | 1 | 2024 | 31 | 0.060 |
Why?
|
Anemia | 1 | 2013 | 1514 | 0.060 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2009 | 497 | 0.060 |
Why?
|
Disease Management | 3 | 2017 | 2533 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2012 | 2456 | 0.050 |
Why?
|
Fatal Outcome | 1 | 2008 | 1838 | 0.050 |
Why?
|
Guideline Adherence | 1 | 2013 | 2234 | 0.050 |
Why?
|
Adenocarcinoma | 2 | 2012 | 6359 | 0.050 |
Why?
|
Boston | 3 | 2017 | 9346 | 0.050 |
Why?
|
Models, Biological | 1 | 2019 | 9461 | 0.050 |
Why?
|
Gadolinium DTPA | 1 | 2006 | 823 | 0.050 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2008 | 732 | 0.050 |
Why?
|
Cohort Studies | 6 | 2016 | 41710 | 0.050 |
Why?
|
Retreatment | 2 | 2017 | 598 | 0.050 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2024 | 348 | 0.050 |
Why?
|
Hydronephrosis | 1 | 2004 | 274 | 0.050 |
Why?
|
Edema | 1 | 2006 | 764 | 0.050 |
Why?
|
Infusions, Intravenous | 1 | 2007 | 2228 | 0.050 |
Why?
|
Pyrimidines | 3 | 2022 | 3043 | 0.050 |
Why?
|
Comorbidity | 2 | 2014 | 10580 | 0.050 |
Why?
|
Fatty Acids, Unsaturated | 1 | 2004 | 539 | 0.050 |
Why?
|
BCG Vaccine | 1 | 2024 | 381 | 0.050 |
Why?
|
Head and Neck Neoplasms | 1 | 2016 | 2929 | 0.050 |
Why?
|
Liver Neoplasms | 3 | 2007 | 4353 | 0.050 |
Why?
|
Benzoxazoles | 1 | 2022 | 92 | 0.050 |
Why?
|
Collagen Type I | 1 | 2004 | 616 | 0.040 |
Why?
|
Lung Neoplasms | 5 | 2008 | 13485 | 0.040 |
Why?
|
Surge Capacity | 1 | 2020 | 48 | 0.040 |
Why?
|
Prostatectomy | 1 | 2008 | 1786 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 3 | 2012 | 20708 | 0.040 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2024 | 3552 | 0.040 |
Why?
|
Tumor Burden | 2 | 2017 | 1900 | 0.040 |
Why?
|
Brain | 2 | 1996 | 27159 | 0.040 |
Why?
|
Interleukin-6 | 2 | 2024 | 3227 | 0.040 |
Why?
|
Double-Blind Method | 1 | 2013 | 12430 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 4 | 2008 | 36567 | 0.040 |
Why?
|
Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2021 | 304 | 0.040 |
Why?
|
Magnetic Resonance Angiography | 1 | 2006 | 1428 | 0.040 |
Why?
|
Urologic Neoplasms | 1 | 2003 | 312 | 0.040 |
Why?
|
Bone Density | 2 | 2014 | 3491 | 0.040 |
Why?
|
Cytokines | 3 | 2024 | 7438 | 0.040 |
Why?
|
Canada | 1 | 2024 | 2126 | 0.040 |
Why?
|
Tyrosine | 1 | 2023 | 1425 | 0.040 |
Why?
|
Neoplasms, Glandular and Epithelial | 1 | 2003 | 488 | 0.040 |
Why?
|
Osteoblasts | 1 | 2004 | 1144 | 0.040 |
Why?
|
Rats, Sprague-Dawley | 4 | 1997 | 8106 | 0.040 |
Why?
|
Morbidity | 1 | 2004 | 1754 | 0.040 |
Why?
|
Dyspnea | 1 | 2006 | 1352 | 0.040 |
Why?
|
Aurintricarboxylic Acid | 1 | 1997 | 10 | 0.040 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2024 | 1105 | 0.040 |
Why?
|
Fluorouracil | 1 | 2003 | 1651 | 0.040 |
Why?
|
Cisplatin | 1 | 2023 | 1655 | 0.030 |
Why?
|
Patient Selection | 2 | 2012 | 4252 | 0.030 |
Why?
|
Genes, fms | 1 | 1996 | 6 | 0.030 |
Why?
|
Remission Induction | 1 | 2003 | 2413 | 0.030 |
Why?
|
Receptors, Interleukin-7 | 1 | 1996 | 41 | 0.030 |
Why?
|
Urinary Bladder | 1 | 2023 | 1155 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-fyn | 1 | 1996 | 114 | 0.030 |
Why?
|
Sulfonamides | 2 | 2018 | 1982 | 0.030 |
Why?
|
Osteopetrosis | 1 | 1996 | 42 | 0.030 |
Why?
|
Bicuculline | 1 | 1996 | 96 | 0.030 |
Why?
|
Multivariate Analysis | 3 | 2017 | 12064 | 0.030 |
Why?
|
Erythropoietin | 1 | 2021 | 718 | 0.030 |
Why?
|
Radioisotopes | 1 | 2018 | 509 | 0.030 |
Why?
|
Receptor, Platelet-Derived Growth Factor beta | 1 | 2017 | 183 | 0.030 |
Why?
|
GABA Antagonists | 1 | 1996 | 119 | 0.030 |
Why?
|
Receptor, Macrophage Colony-Stimulating Factor | 1 | 1996 | 94 | 0.030 |
Why?
|
Controlled Clinical Trials as Topic | 1 | 1997 | 187 | 0.030 |
Why?
|
Skin Neoplasms | 1 | 2016 | 5861 | 0.030 |
Why?
|
Follow-Up Studies | 6 | 2019 | 39309 | 0.030 |
Why?
|
Androgens | 1 | 2003 | 1280 | 0.030 |
Why?
|
Diagnosis, Differential | 2 | 2008 | 12985 | 0.030 |
Why?
|
Collagen | 1 | 2004 | 2635 | 0.030 |
Why?
|
Delivery of Health Care | 1 | 2013 | 5368 | 0.030 |
Why?
|
Cholesterol | 1 | 2004 | 2903 | 0.030 |
Why?
|
Receptors, Interleukin | 1 | 1996 | 243 | 0.030 |
Why?
|
Image Enhancement | 1 | 2006 | 2857 | 0.030 |
Why?
|
Genes, myc | 1 | 1996 | 391 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2023 | 2354 | 0.030 |
Why?
|
Apoptosis | 3 | 1997 | 9513 | 0.030 |
Why?
|
Propensity Score | 1 | 2023 | 1972 | 0.030 |
Why?
|
Contrast Media | 2 | 2006 | 5329 | 0.030 |
Why?
|
Neoplasm Proteins | 1 | 2007 | 3601 | 0.030 |
Why?
|
Radiotherapy Dosage | 1 | 2002 | 2911 | 0.030 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2004 | 3681 | 0.030 |
Why?
|
Risk Factors | 7 | 2017 | 74881 | 0.030 |
Why?
|
Rats | 5 | 1997 | 23717 | 0.030 |
Why?
|
Mutation | 2 | 2016 | 30213 | 0.030 |
Why?
|
Neurites | 1 | 1996 | 389 | 0.030 |
Why?
|
Superior Cervical Ganglion | 1 | 1993 | 33 | 0.030 |
Why?
|
Inflammation | 1 | 2014 | 10860 | 0.030 |
Why?
|
Transplantation, Homologous | 1 | 2003 | 4860 | 0.030 |
Why?
|
Radiopharmaceuticals | 1 | 2024 | 2704 | 0.030 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2016 | 638 | 0.030 |
Why?
|
Risk Assessment | 5 | 2014 | 24295 | 0.030 |
Why?
|
Physician's Role | 1 | 2020 | 925 | 0.030 |
Why?
|
Cells, Cultured | 4 | 1996 | 18984 | 0.030 |
Why?
|
Electrophysiology | 1 | 1996 | 1263 | 0.030 |
Why?
|
Regional Blood Flow | 2 | 2008 | 1478 | 0.030 |
Why?
|
Mice, Mutant Strains | 1 | 1996 | 1751 | 0.030 |
Why?
|
Injections, Intravenous | 1 | 2015 | 1377 | 0.030 |
Why?
|
Animals | 7 | 2024 | 168930 | 0.030 |
Why?
|
Maxilla | 1 | 2016 | 486 | 0.030 |
Why?
|
Signal Transduction | 2 | 2016 | 23619 | 0.030 |
Why?
|
Growth Inhibitors | 1 | 1993 | 375 | 0.030 |
Why?
|
Hospitals, General | 1 | 2017 | 804 | 0.020 |
Why?
|
Cell Hypoxia | 1 | 1994 | 661 | 0.020 |
Why?
|
Disease Susceptibility | 1 | 2019 | 1791 | 0.020 |
Why?
|
Peptides | 1 | 2004 | 4344 | 0.020 |
Why?
|
Fellowships and Scholarships | 1 | 2021 | 1134 | 0.020 |
Why?
|
Intention to Treat Analysis | 1 | 2013 | 418 | 0.020 |
Why?
|
RNA Splicing | 1 | 1996 | 903 | 0.020 |
Why?
|
Models, Statistical | 2 | 2018 | 5091 | 0.020 |
Why?
|
RNA, Messenger | 2 | 1996 | 12791 | 0.020 |
Why?
|
Pyrazoles | 1 | 2022 | 2030 | 0.020 |
Why?
|
Endpoint Determination | 1 | 2014 | 592 | 0.020 |
Why?
|
Echocardiography | 1 | 2024 | 5037 | 0.020 |
Why?
|
Kidney | 1 | 2006 | 7074 | 0.020 |
Why?
|
Marital Status | 1 | 2012 | 426 | 0.020 |
Why?
|
Odds Ratio | 2 | 2014 | 9661 | 0.020 |
Why?
|
Nerve Growth Factors | 1 | 1993 | 564 | 0.020 |
Why?
|
Lymphokines | 1 | 1993 | 924 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2024 | 3944 | 0.020 |
Why?
|
DNA, Neoplasm | 1 | 2016 | 1741 | 0.020 |
Why?
|
Evoked Potentials | 1 | 1996 | 1050 | 0.020 |
Why?
|
Algorithms | 1 | 2010 | 14072 | 0.020 |
Why?
|
Cell Survival | 2 | 1996 | 5748 | 0.020 |
Why?
|
Young Adult | 4 | 2018 | 59939 | 0.020 |
Why?
|
Ischemia | 1 | 1997 | 1905 | 0.020 |
Why?
|
Multicenter Studies as Topic | 1 | 2014 | 1733 | 0.020 |
Why?
|
Angiogenic Proteins | 1 | 2009 | 101 | 0.020 |
Why?
|
United States | 4 | 2021 | 72951 | 0.020 |
Why?
|
Lymphatic Metastasis | 2 | 2007 | 2901 | 0.020 |
Why?
|
Base Sequence | 2 | 1996 | 12415 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor C | 1 | 2008 | 125 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2020 | 3666 | 0.020 |
Why?
|
Geography | 1 | 2010 | 651 | 0.020 |
Why?
|
Injections, Subcutaneous | 1 | 2009 | 684 | 0.020 |
Why?
|
Kidney Transplantation | 1 | 2003 | 4278 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2019 | 2902 | 0.020 |
Why?
|
Up-Regulation | 1 | 1996 | 4142 | 0.020 |
Why?
|
Pregnancy Proteins | 1 | 2008 | 222 | 0.020 |
Why?
|
Genetic Testing | 1 | 2020 | 3591 | 0.020 |
Why?
|
Regression Analysis | 1 | 2016 | 6329 | 0.020 |
Why?
|
Retina | 1 | 1997 | 2660 | 0.020 |
Why?
|
Recombinant Fusion Proteins | 1 | 2015 | 3738 | 0.020 |
Why?
|
Hemodynamics | 1 | 1997 | 4188 | 0.020 |
Why?
|
Molecular Sequence Data | 2 | 1996 | 17608 | 0.020 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2013 | 949 | 0.020 |
Why?
|
Survivors | 1 | 2017 | 2379 | 0.020 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2024 | 9404 | 0.020 |
Why?
|
Antigens, CD | 1 | 1996 | 4032 | 0.020 |
Why?
|
Postoperative Complications | 1 | 2008 | 15831 | 0.020 |
Why?
|
Feasibility Studies | 2 | 2008 | 5306 | 0.020 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2013 | 949 | 0.020 |
Why?
|
Solubility | 1 | 2007 | 1078 | 0.020 |
Why?
|
Phosphorylation | 1 | 1996 | 8307 | 0.020 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2009 | 616 | 0.020 |
Why?
|
Recurrence | 1 | 2017 | 8507 | 0.010 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2007 | 547 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2024 | 18330 | 0.010 |
Why?
|
Proto-Oncogene Proteins | 1 | 1996 | 4522 | 0.010 |
Why?
|
Permeability | 1 | 2006 | 721 | 0.010 |
Why?
|
Probability | 1 | 2009 | 2476 | 0.010 |
Why?
|
Single-Blind Method | 1 | 2007 | 1587 | 0.010 |
Why?
|
Confidence Intervals | 1 | 2009 | 2921 | 0.010 |
Why?
|
Mice | 2 | 2024 | 81889 | 0.010 |
Why?
|
Calibration | 1 | 2006 | 814 | 0.010 |
Why?
|
Spin Labels | 1 | 2005 | 334 | 0.010 |
Why?
|
Microscopy, Electron | 2 | 1997 | 2551 | 0.010 |
Why?
|
Nerve Tissue Proteins | 1 | 1993 | 4400 | 0.010 |
Why?
|
Pandemics | 1 | 2021 | 8735 | 0.010 |
Why?
|
Interleukin-2 | 1 | 2007 | 1895 | 0.010 |
Why?
|
Biopsy | 1 | 2012 | 6779 | 0.010 |
Why?
|
Cluster Analysis | 1 | 2007 | 2717 | 0.010 |
Why?
|
Protons | 1 | 2004 | 1097 | 0.010 |
Why?
|
Cell Differentiation | 1 | 1996 | 11651 | 0.010 |
Why?
|
Aorta | 1 | 2006 | 2043 | 0.010 |
Why?
|
Respiration | 1 | 2004 | 1654 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2015 | 7431 | 0.010 |
Why?
|
Logistic Models | 1 | 2012 | 13278 | 0.010 |
Why?
|
Phantoms, Imaging | 1 | 2006 | 2474 | 0.010 |
Why?
|
Fenfluramine | 1 | 1997 | 58 | 0.010 |
Why?
|
DNA Fragmentation | 1 | 1997 | 238 | 0.010 |
Why?
|
Cyclobutanes | 1 | 1997 | 57 | 0.010 |
Why?
|
Enzyme Inhibitors | 1 | 2007 | 3721 | 0.010 |
Why?
|
Appetite Depressants | 1 | 1997 | 108 | 0.010 |
Why?
|
Health Status | 1 | 2010 | 4087 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2012 | 15416 | 0.010 |
Why?
|
Physicians | 1 | 2014 | 4591 | 0.010 |
Why?
|
Adrenergic beta-Agonists | 1 | 1997 | 345 | 0.010 |
Why?
|
Age Factors | 1 | 2012 | 18397 | 0.010 |
Why?
|
Obesity | 1 | 1997 | 13090 | 0.010 |
Why?
|
Pregnancy | 1 | 1996 | 30237 | 0.010 |
Why?
|
Research Design | 1 | 2010 | 6207 | 0.010 |
Why?
|
Ciliary Neurotrophic Factor | 1 | 1993 | 77 | 0.010 |
Why?
|
Leukemia Inhibitory Factor | 1 | 1993 | 81 | 0.010 |
Why?
|
Fluoxetine | 1 | 1997 | 732 | 0.010 |
Why?
|
Ultrasonography | 1 | 2006 | 5992 | 0.010 |
Why?
|
Genetic Markers | 1 | 1997 | 2603 | 0.010 |
Why?
|
Brain Neoplasms | 1 | 2012 | 9101 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2007 | 7868 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2005 | 8926 | 0.000 |
Why?
|
Animals, Newborn | 1 | 1993 | 2677 | 0.000 |
Why?
|
Kinetics | 1 | 1993 | 6287 | 0.000 |
Why?
|
Energy Metabolism | 1 | 1997 | 2903 | 0.000 |
Why?
|
Analysis of Variance | 1 | 1993 | 6214 | 0.000 |
Why?
|
DNA Damage | 1 | 1993 | 2467 | 0.000 |
Why?
|
Prospective Studies | 1 | 2008 | 54871 | 0.000 |
Why?
|
Chromatin | 1 | 1994 | 2977 | 0.000 |
Why?
|
DNA | 1 | 1994 | 7208 | 0.000 |
Why?
|
Calcium | 1 | 1993 | 5783 | 0.000 |
Why?
|
Cardiovascular Diseases | 1 | 1997 | 15657 | 0.000 |
Why?
|